Healthcare provider profile · identity verified

Stacy Ryan Chance, MD

Internal Medicine · EUGENE, OR · NPI 1356399190

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	498	259
Lisinopril	Lisinopril	339	152
Levothyroxine Sodium	Levothyroxine Sodium	302	148
Amlodipine Besylate	Amlodipine Besylate	233	115
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	231	65
Losartan Potassium	Losartan Potassium	220	106
Oxycodone Hcl	Oxycodone Hcl	205	48
Rosuvastatin Calcium	Rosuvastatin Calcium	143	67
Trazodone Hcl	Trazodone Hcl	136	65
Omeprazole	Omeprazole	133	75
Gabapentin	Gabapentin	127	70
Alprazolam	Alprazolam	120	42
Metoprolol Succinate	Metoprolol Succinate	118	61
Tamsulosin Hcl	Tamsulosin Hcl	116	52
Ozempic	Semaglutide	103	35
Pravastatin Sodium	Pravastatin Sodium	103	52
Eliquis	Apixaban	102	41
Hydrochlorothiazide	Hydrochlorothiazide	99	58
Metformin Hcl Er	Metformin Hcl	98	51
Simvastatin	Simvastatin	93	45
Tramadol Hcl	Tramadol Hcl	92	36
Sertraline Hcl	Sertraline Hcl	90	39
Metoprolol Tartrate	Metoprolol Tartrate	89	43
Furosemide	Furosemide	86	41
Metformin Hcl	Metformin Hcl	86	47
Zolpidem Tartrate	Zolpidem Tartrate	85	37
Buprenorphine Hcl	Buprenorphine Hcl	79	13
Duloxetine Hcl	Duloxetine Hcl	75	36
Potassium Chloride	Potassium Chloride	73	40
Warfarin Sodium	Warfarin Sodium	71	32
Alendronate Sodium	Alendronate Sodium	70	36
Allopurinol	Allopurinol	63	31
Escitalopram Oxalate	Escitalopram Oxalate	62	25
Lorazepam	Lorazepam	62	30
Albuterol Sulfate Hfa	Albuterol Sulfate	59	35
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	59	16
Bupropion Xl	Bupropion Hcl	58	23
Spironolactone	Spironolactone	57	24
Lovastatin	Lovastatin	52	30
Pantoprazole Sodium	Pantoprazole Sodium	51	26
Irbesartan	Irbesartan	50	21
Carvedilol	Carvedilol	49	27
Estradiol	Estradiol	49	26
Jardiance	Empagliflozin	48	21
Tizanidine Hcl	Tizanidine Hcl	48	26
Atenolol	Atenolol	47	23
Clopidogrel	Clopidogrel Bisulfate	47	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	47	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	45	26
Montelukast Sodium	Montelukast Sodium	44	20
Citalopram Hbr	Citalopram Hydrobromide	43	20
Meloxicam	Meloxicam	43	26
Trulicity	Dulaglutide	43	suppressed
Chlorthalidone	Chlorthalidone	42	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	40	23
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	37	suppressed
Ezetimibe	Ezetimibe	37	15
Pregabalin	Pregabalin	37	17
Celecoxib	Celecoxib	36	20
Clonazepam	Clonazepam	36	12
Mirtazapine	Mirtazapine	36	20
Triamcinolone Acetonide	Triamcinolone Acetonide	32	24
Donepezil Hcl	Donepezil Hcl	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	16
Glimepiride	Glimepiride	29	14
Diazepam	Diazepam	28	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	14
Ondansetron Hcl	Ondansetron Hcl	26	14
Paroxetine Hcl	Paroxetine Hcl	26	15
Acyclovir	Acyclovir	24	suppressed
Finasteride	Finasteride	24	12
Propranolol Hcl	Propranolol Hcl	24	11
Famotidine	Famotidine	22	11
Hydroxyzine Hcl	Hydroxyzine Hcl	22	17
Venlafaxine Hcl Er	Venlafaxine Hcl	22	12
Lamotrigine	Lamotrigine	21	suppressed
Torsemide	Torsemide	21	suppressed
Valsartan	Valsartan	21	11
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	11
Amitriptyline Hcl	Amitriptyline Hcl	19	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	16
Verapamil Er	Verapamil Hcl	18	suppressed
Cephalexin	Cephalexin	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	12
Methadone Hcl	Methadone Hcl	17	suppressed
Morphine Sulfate Er	Morphine Sulfate	17	suppressed
Prednisone	Prednisone	17	16
Temazepam	Temazepam	17	suppressed
Buprenorphine	Buprenorphine	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Glipizide	Glipizide	15	suppressed
Nystatin	Nystatin	15	11
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Topiramate	Topiramate	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	12
Candesartan Cilexetil	Candesartan Cilexetil	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Synthroid	Levothyroxine Sodium	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Azithromycin	Azithromycin	12	12
Fluconazole	Fluconazole	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Testosterone	Testosterone	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error